In this special episode in partnership with ESCP Business School, I’m joined by Clarissa Gorin, a pharmacist and ESCP Business School MSc Biopharmaceutical Management alum, who transitioned from the blockchain industry to head Medical Affairs at Ad Scientiam, a MedTech company specializing in digital biomarkers. Clarissa shares her journey from a traditional pharmacy career path to embracing tech innovation in healthcare, particularly in the fight against counterfeit medicines in developing countries. Her work at Ad Scientiam, which originated from the Paris Brain Institute, focuses on creating digital biomarkers using smartphone sensors and AI to monitor and predict the progression of neurodegenerative diseases. Clarissa's unique perspective highlights the importance of adaptability and the practical application of technology to meet real-world needs in the healthcare sector. Throughout the episode, we dive into Clarissa's experiences in navigating cultural challenges in tech adoption, particularly in developing regions, and how this has shaped her approach to leading innovative projects. She emphasizes the value of understanding the specific needs of both patients and healthcare providers when developing new technologies, and the critical role that digital biomarkers and AI can play in the future of medical diagnostics and treatment. Clarissa also reflects on the importance of accessibility and humility in tech development, ensuring that solutions are not only high-tech but also practical and adaptable to diverse healthcare settings around the world. "Effective leadership hinges on adaptability and the ability to respond swiftly to change." MEET OUR GUEST Clarissa Gorin, Head of Medical Innovation, Medical Affairs at Ad scientam. Clarissa holds a dual degree in Pharmacy and a Master of Science (MSc) specialized in pharmaceutical and biotechnology management from ESCP Business School. She quickly developed a keen interest in emerging technologies, data management, and their applications in the healthcare sector. Following her initial professional experience focusing on the blockchain industry and the fight against counterfeit medicines in developing countries, Clarissa joined Ad Scientiam in 2020 as Head of Medical Affairs. Ad Scientiam, a MedTech company originating from the Paris Brain Institute, specializes in developing digital biomarkers that enable the monitoring and prediction of the progression of certain neurodegenerative pathologies and rare diseases. These innovative markers are derived from proprietary algorithms for measuring precise analysis movements, vocal activity, or image processing derived from smartphone sensors and AI technologies. Within Ad Scientiam, her role involves working collaboratively with the Scientific Board to ensure the development and validation of these biomarkers, leveraging her medical knowledge and expertise.